Although the molecular mechanism of SC-1 action needs to be further clarified, our data strongly suggest that SC-1 inhibits IL-6 production and will provide additional benefit in the management of the disease, which prevents tumor cells resistant to the TGFβ’s tumor suppression activity in cancers. The gene discussed is IL6; the disease is neoplasm.